Bicycle Therapeutics Plc ADR (BCYC) Stock Price, Quote & News

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing t...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 1223 261 503

Website: www.bicycletherapeutics.com

Address:

Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom

eladfff Aug. 22 at 7:51 PM

$BCYC Point72 still selling, constant weight pushing down. Sold 2M shares in 2nd Q and had 2M left, probably take the whole 3rd Q before they're done and that selling pressure is relieved. Probably other funds in no rush to help Point72 by putting out big bids

0 · Reply

SQUEAKSBANDIT Aug. 21 at 12:22 AM

$BCYC https://firstwordpharma.com/story/5921472 bakers bought very large AFTER this data hit in dec shares down over 50% since they bought

0 · Reply

SQUEAKSBANDIT Aug. 20 at 6:28 PM

$BCYC i'm kinda shocked that we have a chance to add under 7 despite the filing the brothers haven't sold a share and aren't committed to sell any

1 · Reply

SQUEAKSBANDIT Aug. 20 at 6:11 PM

$BCYC broke under 7 on anemic volume took some

0 · Reply

eladfff Aug. 19 at 8:20 PM

$BCYC Ready for fresh lows. Just a little hard to believe with Julian and Felix having put literally half a billion dollars into this from $20/sh. Head-scratcher. Possibly those clowns at Point-72 are still finishing up selling the several million shares they bought less than a year ago. They had sold 3M of their 5M shares by the end of the 2nd Q.

1 · Reply

eladfff Aug. 14 at 8:17 PM

$BCYC Only a 50¢ fade today

0 · Reply

SQUEAKSBANDIT Aug. 14 at 7:52 PM

$BCYC anyone been trading the intraday volatility this name has been such a laggard but money can be made flipping moves fast

0 · Reply

eladfff Aug. 14 at 3:39 AM

$BCYC 77¢ fade after acting for half an hour like it wanted to participate

0 · Reply

eladfff Aug. 12 at 8:51 PM

$BCYC Absolute garbage with XBI ripping. BT1718 quietly abandoned, BT8009 efficacy looks inferior to Padcev in mUC, BT5528 and BT7480 early data looks terrible, Genentech partnership termination, layoffs, mixed shelf filing for an amount greater than current MC, BB's filing to be able to sell their 30M shares, downgrades and PT cuts... Seems very bad rt now. I guess that makes the question whether they're approaching "max badness". Or whether there's worse yet to come.

0 · Reply

anachartanalyst Aug. 12 at 2:02 PM

$BCYC https://anachart.com/wp-content/uploads/ana_temp/1755007338_soc-img.jpg

0 · Reply

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 2, 2025, 4:05 PM EDT - 7 weeks ago

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2025, 5:05 PM EDT - 3 months ago

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

May 1, 2025, 7:00 AM EDT - 4 months ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Apr 22, 2025, 3:47 AM EDT - 4 months ago

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 5 months ago

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Feb 25, 2025, 7:00 AM EST - 6 months ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 7 months ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 2, 2025, 5:26 AM EST - 7 months ago

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Jan 13, 2025, 7:00 AM EST - 7 months ago

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Jan 9, 2025, 7:00 AM EST - 8 months ago

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 6:30 PM EST - 9 months ago

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Dec 10, 2024, 7:00 AM EST - 9 months ago

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Nov 25, 2024, 5:30 PM EST - 9 months ago

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Nov 12, 2024, 7:00 AM EST - 10 months ago

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 10:04 AM EST - 10 months ago

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Oct 31, 2024, 7:00 AM EDT - 10 months ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 23, 2024, 7:00 AM EDT - 10 months ago

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Oct 16, 2024, 7:00 AM EDT - 11 months ago

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Sep 6, 2024, 1:37 PM EDT - 1 year ago

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Aug 20, 2024, 7:37 AM EDT - 1 year ago

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 6, 2024, 7:05 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aug 6, 2024, 7:00 AM EDT - 1 year ago

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

BSY MASS MLI NJR OFIX QBTS SMMT

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

May 23, 2024, 5:05 PM EDT - 1 year ago

Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

May 23, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 25, 2024, 1:07 PM EDT - 1 year ago

2 More Potential Biotech Buyout Targets

AZN BMY EXEL LLY MRK NVS TAK

Mar 12, 2024, 12:09 PM EDT - 1 year ago

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 5, 2024, 4:35 PM EST - 1 year ago

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Feb 20, 2024, 7:05 AM EST - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 14, 2023, 7:00 AM EST - 1 year ago

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Nov 30, 2023, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Host R&D Day on December 14

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Oct 19, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

Oct 19, 2023, 4:00 AM EDT - 2 years ago

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 3, 2023, 6:59 AM EDT - 2 years ago

Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 31, 2023, 7:07 PM EDT - 2 years ago

Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due

Jul 18, 2023, 7:00 AM EDT - 2 years ago

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 12, 2023, 10:23 PM EDT - 2 years ago

Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

Jul 12, 2023, 4:01 PM EDT - 2 years ago

Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

eladfff Aug. 22 at 7:51 PM

0 · Reply

SQUEAKSBANDIT Aug. 21 at 12:22 AM

$BCYC https://firstwordpharma.com/story/5921472 bakers bought very large AFTER this data hit in dec shares down over 50% since they bought

0 · Reply

SQUEAKSBANDIT Aug. 20 at 6:28 PM

$BCYC i'm kinda shocked that we have a chance to add under 7 despite the filing the brothers haven't sold a share and aren't committed to sell any

1 · Reply

SQUEAKSBANDIT Aug. 20 at 6:11 PM

$BCYC broke under 7 on anemic volume took some

0 · Reply

eladfff Aug. 19 at 8:20 PM

1 · Reply

eladfff Aug. 14 at 8:17 PM

$BCYC Only a 50¢ fade today

0 · Reply

SQUEAKSBANDIT Aug. 14 at 7:52 PM

$BCYC anyone been trading the intraday volatility this name has been such a laggard but money can be made flipping moves fast

0 · Reply

eladfff Aug. 14 at 3:39 AM

$BCYC 77¢ fade after acting for half an hour like it wanted to participate

0 · Reply

eladfff Aug. 12 at 8:51 PM

0 · Reply

anachartanalyst Aug. 12 at 2:02 PM

$BCYC https://anachart.com/wp-content/uploads/ana_temp/1755007338_soc-img.jpg

0 · Reply

JarvisFlow Aug. 12 at 1:01 PM

JMP Securities has updated their rating for Bicycle Therapeutics ( $BCYC ) to Market Outperform with a price target of 10.

0 · Reply

JarvisFlow Aug. 12 at 12:30 PM

Morgan Stanley has adjusted their stance on Bicycle Therapeutics ( $BCYC ), setting the rating to Equal-Weight with a target price of 17 → 13.

0 · Reply

JarvisFlow Aug. 11 at 1:07 PM

Oppenheimer has updated their rating for Bicycle Therapeutics ( $BCYC ) to Outperform with a price target of 44.

0 · Reply

biochirp Aug. 9 at 12:25 AM

$BCYC

1 · Reply

d_risk Aug. 8 at 2:43 PM

$BCYC - Bicycle Therapeutics plc American Depositary Shares - 10Q - Updated Risk Factors BCYC flags heightened risks tied to dependence on internal BDC and TICA programs, ongoing clinical trial enrollment hurdles, and the unpredictable, costly path to marketing approval, while expanding detail on existing financial, regulatory, and operational risks. #Biotechnology #OperationalRisk #FinancialRisk #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/BCYC/10-Q/2025-08-08

0 · Reply

eladfff Aug. 5 at 5:43 PM

$BCYC DEAD money. Sort of surprising that it can't bounce with XBI when Felix owns 30M+ of the 69M shares outstanding - and from $20+ apiece - but you can't argue with the complete lack of anything positive from the company in the past 14 months. Since May of last year when Felix bought 19M+ of the $21.42/apiece ADS's in the PIPE offering. Only mediocre early-phase trial data and zero other compelling business updates since then.

2 · Reply